The first-line treatment for non-muscle invasive bladder cancer (NMIBC) is intravesical Bacillus CalmetteGuerin (BCG). Despite BCG, alternative treatments are urgently required for recurrent or progressive bladder cancer. Cystectomy is the gold standard treatment in BCG failure in bladder cancer. When cystectomy can not be performed for reasons related to the patient, other treatments should be started. Many clinical studies such as intravesical gemcitabine, taxanes or combination treatment, new therapeutic agents,..etc are critical in determining the next step. Alternative to radical cystectomy, well designed and many new treatment studies are still ongoing. They seem ready for routine clinical practice in the near future. We believe that ...
Intravesical bacillus Calmette–Guérin (BCG) immunotherapy has been the gold standard adjuvant treatm...
Bladder cancer is the 10th most frequently diagnosed cancer worldwide with 5-year survival rate arou...
Non-muscle invasive bladder cancer (NMIBC) has traditionally been managed with transurethral resecti...
Bladder cancer is the ninth-most prevalent cancer worldwide. Most patients with urothelial cell carc...
Non-muscle invasive bladder cancer (NMIBC) is a common and burdensome malignancy. A substantial prop...
Non-muscle invasive bladder cancer is marked by frequent recurrences and a risk for progression to l...
CONTEXT: Intravesical bacillus Calmette-Guerin (BCG) is a standard conservative treatment for patien...
Transitional cell carcinoma (TCC) is the second most common urologic malignancy, and 70% of patients...
Transitional cell carcinoma (TCC) is the second most common urologic malignancy, and 70% of patients...
Item does not contain fulltextCONTEXT: Intravesical bacillus Calmette-Guerin (BCG) is a standard con...
Urothelial carcinoma (UC), the sixth most common cancer in Western countries, includes upper tract u...
Bladder cancer (BC) is one of the leading causes of cancer-related deaths worldwide. Despite, the ma...
Patients with high-grade Ta, T1, or carcinoma in situ non–muscle-invasive bladder cancer (NMIBC) are...
Non-muscle-invasive bladder cancer (NMIBC) is characterized by a high rate of cure, but also by a no...
Intravesical bacillus Calmette-Guerin (BCG) therapy is the gold standard treatment option in high-ri...
Intravesical bacillus Calmette–Guérin (BCG) immunotherapy has been the gold standard adjuvant treatm...
Bladder cancer is the 10th most frequently diagnosed cancer worldwide with 5-year survival rate arou...
Non-muscle invasive bladder cancer (NMIBC) has traditionally been managed with transurethral resecti...
Bladder cancer is the ninth-most prevalent cancer worldwide. Most patients with urothelial cell carc...
Non-muscle invasive bladder cancer (NMIBC) is a common and burdensome malignancy. A substantial prop...
Non-muscle invasive bladder cancer is marked by frequent recurrences and a risk for progression to l...
CONTEXT: Intravesical bacillus Calmette-Guerin (BCG) is a standard conservative treatment for patien...
Transitional cell carcinoma (TCC) is the second most common urologic malignancy, and 70% of patients...
Transitional cell carcinoma (TCC) is the second most common urologic malignancy, and 70% of patients...
Item does not contain fulltextCONTEXT: Intravesical bacillus Calmette-Guerin (BCG) is a standard con...
Urothelial carcinoma (UC), the sixth most common cancer in Western countries, includes upper tract u...
Bladder cancer (BC) is one of the leading causes of cancer-related deaths worldwide. Despite, the ma...
Patients with high-grade Ta, T1, or carcinoma in situ non–muscle-invasive bladder cancer (NMIBC) are...
Non-muscle-invasive bladder cancer (NMIBC) is characterized by a high rate of cure, but also by a no...
Intravesical bacillus Calmette-Guerin (BCG) therapy is the gold standard treatment option in high-ri...
Intravesical bacillus Calmette–Guérin (BCG) immunotherapy has been the gold standard adjuvant treatm...
Bladder cancer is the 10th most frequently diagnosed cancer worldwide with 5-year survival rate arou...
Non-muscle invasive bladder cancer (NMIBC) has traditionally been managed with transurethral resecti...